Anna D. Barker, chief strategy officer at the Lawrence J. Ellison Institute for Transformative Medicine is the recipient of the AIM-HI Accelerator Fund’s inaugural Beacon Award for Women Leaders in Oncology.
Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine issued a call for proposals for the 2023 Harrington-Medical Scientist Training Program Scholar Award to help the next generation of physician-scientists advance their discoveries towards clinical application.
ViewRay Inc. began a phase III randomized controlled trial titled “Locally Advanced Pancreatic cancer treated with ABLATivE stereotactic MRI-guided adaptive radiation therapy”—also known as LAP-ABLATE—which will compare stand-alone multi-agent chemotherapy, which is the current standard of care for patients with locally advanced pancreatic cancer, to patients receiving a combination of chemotherapy and 5-fraction MRIdian stereotactic MR-guided adaptive radiotherapy.
Feng Yang’s lab at Baylor College of Medicine published a study in the Proceedings of the National Academy of Sciences, which looked into what drives the growth of advanced tumors that have become resistant to standard castration therapy. Working with cells in the lab and animal models, they discovered an approach that suppresses the growth of therapy-resistant tumors.
Scott Verbridge, associate professor in biomedical engineering and mechanics at Virginia Tech, and Barath Udayasuryan, an alumnus from the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, have discovered a characteristic of a common oral bacterium that relocates to pancreatic cancer tumors which may help guide future therapeutic interventions for treatment.
FDA issued a final guidance, “Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment.”
FDA issued a draft guidance, “Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials.”
FDA issued a draft guidance, “Tissue Agnostic Drug Development in Oncology.”
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a radioligand therapy, in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with progressive prostate-specific membrane antigen-positive, metastatic, castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane based chemotherapy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
